Premature ejaculation – definition, classification and therapy. Part II
Keywords:
premature ejaculation, diagnosis, treatmentAbstract
Premature ejaculation (PE) and erectile dysfunction (ED, impotence) are the two main complaints in male sexual medicine. It can affect men at all ages and has a serious impact on the quality of life for men and their partners. Although PE is a very common male sexual dysfunction, it is poorly understood. Patients are often unwilling to discuss their symptoms and many physicians do not know about effective treatments. Therapy should involve the man and his partner (mainly psychotherapy and sexual education). The primary aims of therapy are for the man to extend the intravaginal ejaculation latency time (IELT), to regain a sense of control over his ejaculation time and for him and his partner to feel satisfaction with sexual intercourse. The most effective therapies for PE are: tricyclic antidepressants, certain selective serotonin reuptake inhibitors (SSRI, mainly dapoxetine), serotonin antagonist and reuptake inhibitor (SARI) and phosphodiesterase type 5 inhibitors (PDE-5),given on a daily basis or “on demand” before sexual activity. Topical anaesthetics have also been shown to be effective. The aim of the study is to describe the prevalence, the diagnosis and the classification of the PE. In the second part the main issues which are connected with biological therapy (pharmacotherapy) of the PE were described.
References
1. Hatzimouratidis K., Amar E., Eardley I., Giuliano F., Hatzichristou D., Montorsi F., Vardi Y., Wespes E. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. Eur. Urol., 2010; 57: 804-814.
2. Palmer N.R., Bronwyn G.A. Stuckey. Premature ejaculation: a clinical update. MJA, 2008; 188: 662-666.
3. Kendirci M., Salem E., Hellstrom W.J.G. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther. Clin. Risk Manag., 2007; 3(2): 277-289.
4. Gurkan L., Oommen M., Hellstrom W.J.G. Premature ejaculation: current and future treatments. Asian. J. Androl, 2008; 10 (1): 102-109.
5. Masters W., Johnson V. Human Sexual Inadequacy. Boston: Little Brown and Company; 1970.
6. Semans J. Premature ejaculation; a new approach. South Med J., 1956; 49: 353-358.
7. Waldinger M.D. Premature ejaculation: state of the art. Urol. Clin. North. Am., 2007; 34: 591-599.
8. Metz M.E., Pryor J.L., Nesvacil L.J., Abuzzahab Sr F., Koznar J. Premature ejaculation: a psychophysiological review. J. Sex. Marital Ther., 1997; 23: 3-23.
9. Abdel-Hamid I.A., El Naggar E.A., El Gilany A.H. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int. J. Impot. Res, 2001;13: 41-45.
10. Salem E.A., Wilson S.K., Bissada N.K., Delk J.R., Hellstrom W.J., Cleves M.A. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J. Sex. Med., 2008; 5(1): 188-193.
11. Linton K.D., Wylie K.R. Recent advances in the treatment of premature ejaculation. Drug Des. Devel Ther., 2010; 4: 1-6.
12. Waldinger M.D., Zwinderman A.H., Schweitzer D.H., Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int. J. Impot. Res., 2004; 16: 369-381.
13. Waldinger M.D., Zwinderman A.H., Olivier B. On – demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double blind, fixed –dose study with stopwatch assessment. Eur. Urol., 2004; 45: 510-516.
14. Palmer N.R., Bronwyn G.A. Stuckey. Premature ejaculation: a clinical update. MJA, 2008; 188: 662-666.
15. Althof S.E., Levine S.B., Corty E.W., Risen CB, Stern EB, Kurit DM. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J. Clin. Psychiatry, 1995; 56: 402-407.
16. Haensel S.M., Rowland D.L., Kallan K.T. Clomipramine and sexual function in men with premature ejaculation and controls. J. Urol., 1996, 156: 1301-1315.
17. Seagraves R.T., Saran A, Segraves K, Maguire E. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J. Sex. Martial Ther., 1993; 19: 198-200.
18. Waldinger M.D., Hengeveld M.W., Zwinderman A.H., Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fl uoxetine, fl uvoxamine, paroxetine, and sertraline. J. Clin. Psychopharmacol., 1998b; 18(4): 274-281.
19. Kucia K., Delkowski R.S. Dysfunkcje seksualne wywołane przez leki przeciwdepresyjne. Wiad. Lek., 2005; 58(11–12): 660-664.
20. Hellstrom W.J.G. Emerging treatments for premature ejaculation: focus on dapoxetine. Neuropsychiatr. Dis. Treat., 2009; 5: 37-46.
21. Waldinger M.D., Zwinderman A.H., Schweitzer D.H., Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int. J. Impot. Res., 2004; 16: 369-381.
22. Arafa M., Shamloul R. A randomized study examining the effect of 3SSRI on premature ejaculation using a validated Questionnaire. Ther. Clin. Risk Manag., 2007; 3(4): 527-531.
23. Dadfar M.R., Baghinia M.R. Salvage use of citalopram for treatment of fluoxetine-resistant premature ejaculation in recently married men a prospective clinical trial. Urol. J., 2010; 7: 40-44.
24. Neill JR. Penile anaesthesia associated with fluoxetine use. Am. J. Psychiat., 1991; 148: 1603.
25. Hellstrom W.J.G. Emerging treatments for premature ejaculation: focus on dapoxetine. Neuropsychiatr. Dis. Treat., 2009; 5: 37-46.
26. Montejo A.L., Llorca G., Izquierdo J.A., Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry., 2001; 62(suppl 3): 10-21.
27. Andersson K.E., Mulhall J.P., Wyllie M.G. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for “on demand” treatment of premature ejaculation. BJU Int., 2006; 97: 311-315.
28. Buvat J., Tesfaye F., Rothman M. Dapoxetine for the treatment of premature ejaculation: results from randomised, double-blind, placebo – controlled phase 3 trial in 22 countries. Eur. Urol., 2009; 4: 957-968.
29. Modi N.B., Dresser M.J., Simon M., Lin D., Desai D., Gupta S. Single and multiple dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J. Clin. Pharmacol., 2006; 46(3): 301-309.
30. Pryor J.L., Althof S.E., Steidle C., Rosen R.C., Hellstrom W.J., Shabsigh R., Miloslavsky M., Kell S., Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomizedcontrolled trials. Lancet, 2006; 368(9539): 929-937.
31. Wang Y., Mao Y., Wei Q., Wu T., Dong Q. Dapoxetine in treatment of premature ejaculation: a systematic review. J. Peking Univ. (Health Sciences), 2010; 42(4): 425-432.
32. Haria M., Fitton A., McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging, 1994; 4: 331-355.
33. Kaynak H., Kaynak D., Gozukirmizi E., Guilleminaul C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Medicine, 2004; 5: 15–20.
34. Landowski J., Cubała W.J. Trazodon — charakterystyka kliniczna i farmakologiczna. Psychiatria, 2005; 2: 135–144.
35. Stryjer R., Spivak B., Strous R.D., Shiloh R., Harary E., Polak L., Birgen M., Kotler M., Weizman A. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin. Neuropharmacol., 2009; 32(2): 82-84.
36. Lal S. Treatment of impotence with trazodone. A case report. J. Urol., 1990; 143: 819-820.
37. Warner M.D., Peabody C.A., Whiteford H.A. Trazodone and priapism. J. Clin. Psychiatry, 1987; 48: 244-245.
38. Rosen R.C., Ashton A.K. Prosexual drugs: empirical status of the “new aphrodisiacs. Arch. Sex. Behav., 1993; 22: 521-543.
39. Schapiro B. Premature ejaculation, a review of 1130 cases. J. Urol., 1943; 50: 374.
40. Busato W., Galindo C.C. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebocontrolled study. BJU Int., 2004; 93: 1018-1021.
41. Choi H.K., Jung G.W., Moon K.H., Xin ZC, Choi YD, Lee WH, Rha KH, Choi YJ, Kim DK. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology, 2000; 55: 257-261.
42. Xin Z.C., Choi Y.D., Lee S.H., Choi H.K. Efficacy of a topical agent SScrem in the treatment of premature ejaculation: Preliminary clinical studies. J. Korean Androl. Soc., 1997; 38: 91-95 .
43. Xin Z.C., Chung W.S., Choi Y.D., Seong D.H., Choi Y.J., Choi H.K., Chung Z.C., Penile sensitivity in patients with primary premature ejaculation. J. Urol., 1996; 156: 979-981
44. Lew-Starowicz Z. Inhibitory fosfodiesterazy typu 5 - podobieństwa i różnice. Seksuol. Pol., 2003; 1(2): 79-82.
45. Ekmekcioglu O. The effect of Sildenafil citrate on ejaculatory latency time, detumescence period and second erection. Int. J. Imp. Res., 2003; 15 (supl.): 49.
46. Belowska-Bień K., Zdrojewicz Z. Współczesne leczenie zaburzeń erekcji w praktyce lekarza rodzinnego. Przew. Lek., 2004; 1: 81-83.
47. Angulo J., Gadau M., Fernabdez A. IC351 enhances NO-mediated relaxation of human arterial and trabecular penile smooth muscle. Eur. Urol., 2001; 39 (suppl. 5): abstract 415.
48. Porst H., Vardi Y., Akkus E., Melman A., Park N.C., Seftel A.D., Teloken C., Wyllie M. Standards for clinical trials in male sexual dysfunctions. J. Sex. Med., 2010; 414-444.
49. Aversa A., Pili M., Francomano D., Bruzziches R., Spera E., La Pera G., Spera G. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int. J. Impot. Res., 2009; 21(4): 221-227.
50. Beretta G., Chelo E., Fanciullacci F., Zanollo A., Effect of an alphablocking agent (phenoxybenzamine) in the management of premature ejaculation. Acta Eur. Fertil., 1986; 17: 43-45
51. Basar M.M., Yilmaz E., Ferhat M., Başar H., Batislam E., Terazosin in the treatment of premature ejaculation: a short –term follow – up. Int. Urol. Nephrol., 2005; 37: 773-777
52. Cavallini G. Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Eur Urol, 1995; 28: 126–130.
53. Powell J.A., Wyllie M.G. ‘Up and coming’ treatments for premature ejaculation: progress towards an approved therapy. Int. J. Impot. Res., 2009; 21:107–115.
54. Fein R.L. Intracavernous medication for treatment of premature ejaculation. Urology, 1990; 35:301-303 .
55. Purvis K., Egdetveit I., Christiansen E. Intracavernosal therapy for erectile failure _ Impact of treatment and reasons for drop-out and dissatisfaction. In. J. Impot. Res., 1999; 11: 287-299
56. Fischer Santos B.O., deDues Vieira L.A., Fischer R. Neurotomy: a new technique for the treatment of premature ejaculation. Int. J. Impot. Res., 2001; 13(Suppl 1): 11.
57. Romero A.D., Rebello S.F. The selective neurotomy of the dorsal nerve of penis: A new approach in the treatment of true premature ejaculation. In. J. Impot. Res., 1994; 6 (Suppl 1) Abstract V 23.
58. Kim J.J., Kwak TI, Jeon BG, Cheon J, Moon DG., Effects of glans penis augmentation using hyaluronic acid gel for premature ejaculation. Int J. Impot. Res., 2004; 16: 547-551.
59. Salonia A., Maga T, Colombo R, Scattoni V, Briganti A, Cestari A, Guazzoni G, Rigatti P, Montorsi F. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J. Urol., 2002; 168: 2486-2489.
60. Metin A., Kayigil O., Ahmed S.I. Does lidocaine ointment addition increase fluxetine efficacy in the same group of patients with premature ejaculation? Urol. Int., 2005; 75: 231-234.
61. Atan A., Basar M.M., Aydoganli L. Comparison of the efficacy of fluoxetine alone versus fluoxetine plus local lidocaine ointment in the treatment of premature ejaculation. Arch. Esp. Urol., 2000; 53: 856-858.
62. Atan A., Basar MM, Tuncel A, Ferhat M, Agras K, Tekdogan U. Comparison of the efficacy of sildenafil – only sildenafil plus topical EMLA cream, and topical EMLA –cream – only in treatment of premature ejaculation. Urology, 2006; 67: 388-389
63. Payne R., Sadovsky R. Identifying and treating premature ejaculation: Importance of the sexual history. Cleve. Clin. J. Med., 2007; 74(3): 47-53.
64. Wespes E, Amar E., Eardley I., Giuliano F., Hatzichristou D., Hatzimouratidis K., Montorsi F., Vardi Y. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. European Association of Urology, 2010.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
